Soleno Therapeutics (SLNO) Intangibles (2015 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Intangibles of $4.4 million for Q1 2026, down 30.77% year-over-year from $6.3 million in Q1 2025, and down 10.02% quarter-over-quarter from $4.9 million in Q4 2025.
Soleno Therapeutics (SLNO) Intangibles (2015 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Intangibles for 12 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 30.77% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $4.4 million (down 30.77% YoY), while the FY2025 annual figure was $4.9 million, down 28.57% from the prior year.
- Intangibles declined to $4.4 million in Q1 2026 per SLNO's latest filing, from $4.9 million in the prior quarter.
- Across five years, Intangibles topped out at $12.2 million in Q1 2022 and bottomed at $4.4 million in Q1 2026.
- Historically, Intangibles has averaged $8.3 million across 5 years, with a median of $8.3 million in 2024.
- Annual changes were most pronounced in 2022 — Intangibles fell 13.79% — and 2026, when it sank 30.77%.
- Soleno Therapeutics' Intangibles stood at $10.7 million in 2022, then dropped by 18.18% to $8.7 million in 2023, then declined by 22.22% to $6.8 million in 2024, then fell by 28.57% to $4.9 million in 2025, then retreated by 10.02% to $4.4 million in 2026.
- Business Quant data shows SLNO's Intangibles at $4.4 million in Q1 2026, $4.9 million in Q4 2025, and $5.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 4.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.37 Mn |
| Dec 31, 2025 | 4.86 Mn |
| Sep 30, 2025 | 5.35 Mn |
| Jun 30, 2025 | 5.83 Mn |
| Mar 31, 2025 | 6.32 Mn |
| Dec 31, 2024 | 6.81 Mn |
| Sep 30, 2024 | 7.29 Mn |
| Jun 30, 2024 | 7.78 Mn |
| Mar 31, 2024 | 8.26 Mn |
| Dec 31, 2023 | 8.75 Mn |
| Sep 30, 2023 | 9.24 Mn |
| Jun 30, 2023 | 9.72 Mn |
| Mar 31, 2023 | 10.21 Mn |
| Dec 31, 2022 | 10.69 Mn |
| Sep 30, 2022 | 11.18 Mn |
| Jun 30, 2022 | 11.67 Mn |
| Mar 31, 2022 | 12.15 Mn |
| Dec 31, 2021 | 12.64 Mn |
| Sep 30, 2021 | 13.12 Mn |
| Jun 30, 2021 | 13.61 Mn |